These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23053498)

  • 1. Elevation of serum C-reactive protein predicts failure of the initial antimicrobial treatment for febrile neutropenia with lung cancer.
    Matsumoto T; Fujita M; Hirota T; Takeda S; Hirano R; Uchino J; Harada T; Watanabe K
    J Infect Chemother; 2013 Apr; 19(2):202-7. PubMed ID: 23053498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying risk factors for refractory febrile neutropenia in patients with lung cancer.
    Fujita M; Tokunaga S; Ikegame S; Harada E; Matsumoto T; Uchino J; Watanabe K; Nakanishi Y
    J Infect Chemother; 2012 Feb; 18(1):53-8. PubMed ID: 21773751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentraxin-3 as a Biomarker for Febrile Neutropenia in Patients with Lung Cancer.
    Takeda N; Asai K; Ijiri N; Yamamoto N; Watanabe T; Kamoi H; Kanazawa H; Hirata K
    Osaka City Med J; 2015 Jun; 61(1):43-52. PubMed ID: 26434104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefepime monotherapy for febrile neutropenia in patients with lung cancer.
    Saito H; Takahashi K; Okuno M; Saka H; Imaizumi K; Hasegawa Y; Tanikawa Y; Yamamoto M; Taniguchi H; Shindoh J; Suzuki R; Shimokata K;
    J Infect Chemother; 2014 Jun; 20(6):365-9. PubMed ID: 24679653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10.
    Uys A; Rapoport BL; Fickl H; Meyer PW; Anderson R
    Eur J Cancer Care (Engl); 2007 Nov; 16(6):475-83. PubMed ID: 17944761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of time to antibiotics on outcomes of chemotherapy-induced febrile neutropenia.
    Ko BS; Ahn S; Lee YS; Kim WY; Lim KS; Lee JL
    Support Care Cancer; 2015 Sep; 23(9):2799-804. PubMed ID: 25663578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia.
    Ahn S; Lee YS; Chun YH; Kwon IH; Kim W; Lim KS; Kim TW; Lee KH
    Support Care Cancer; 2011 Aug; 19(8):1151-8. PubMed ID: 20552376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An audit of febrile neutropenia cases from a rural cancer center in India.
    Patil VM; Chakarborty S; Kumar MS; Geetha M; Dev S; Samuel S; Ahmed G; Nayanar SK; Vineetha R; Nair CK
    Indian J Cancer; 2014; 51(4):487-90. PubMed ID: 26842173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
    Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
    Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretherapeutic Inflammation Predicts Febrile Neutropenia and Reduced Progression-Free Survival after First-Line Chemotherapy in SCLC.
    Kauffmann-Guerrero D; Kahnert K; Syunyaeva Z; Tufman A; Huber RM
    Oncol Res Treat; 2018; 41(9):506-512. PubMed ID: 30086542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
    Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
    Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for refractory febrile neutropenia in urological chemotherapy.
    Yasufuku T; Shigemura K; Tanaka K; Arakawa S; Miyake H; Fujisawa M
    J Infect Chemother; 2013 Apr; 19(2):211-6. PubMed ID: 23011233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy-associated febrile neutropenia presenting to an emergency department.
    García de Guadiana-Romualdo L; Cerezuela-Fuentes P; Español-Morales I; Esteban-Torrella P; Jiménez-Santos E; Hernando-Holgado A; Albaladejo-Otón MD
    Biochem Med (Zagreb); 2019 Feb; 29(1):010702. PubMed ID: 30591812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can MASCC and CISNE scores predict delays of lung cancer chemotherapy after febrile neutropenia?
    Ono Y; Hayama N; Hattori S; Ito Y; Oguma T; Sakamaki F; Asano K
    Thorac Cancer; 2022 Dec; 13(24):3504-3509. PubMed ID: 36330990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy and safety of cefepime in febrile neutropenic patients with lung cancer.
    Fujita M; Ouchi H; Inoue Y; Inoshima I; Ohshima T; Yoshimura C; Wataya H; Kawasaki M; Tokunaga S; Nakanishi Y;
    J Infect Chemother; 2010 Apr; 16(2):113-7. PubMed ID: 20130951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms.
    Combariza JF; Lombana M; Pino LE; Arango M
    Support Care Cancer; 2015 Apr; 23(4):1009-13. PubMed ID: 25270848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.
    Uys A; Rapoport BL; Anderson R
    Support Care Cancer; 2004 Aug; 12(8):555-60. PubMed ID: 15197637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of ED and direct admission care of cancer patients with febrile neutropenia.
    Owolabi DK; Rowland R; King L; Miller R; Hegde GG; Shang J; Lister J; Venkat A
    Am J Emerg Med; 2015 Jul; 33(7):966-9. PubMed ID: 25959844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of cefepime or meropenem in the treatment of febrile neutropenia in patients with lung cancer. A randomized phase II study.
    Fujita M; Matsumoto T; Inoue Y; Wataya H; Takayama K; Ishida M; Ebi N; Kishimoto J; Ichinose Y;
    J Infect Chemother; 2016 Apr; 22(4):235-9. PubMed ID: 26867793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outpatient treatment with intravenous antimicrobial therapy and oral levofloxacin in patients with febrile neutropenia and hematological malignancies.
    Bellesso M; Costa SF; Pracchia LF; Santos Dias LC; Chamone D; Dorlhiac-Llacer PE
    Ann Hematol; 2011 Apr; 90(4):455-62. PubMed ID: 20852999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.